

Sofie Struyf

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/9363611/publications.pdf](https://exaly.com/author-pdf/9363611/publications.pdf)

Version: 2024-02-01

164
papers

13,155
citations

20634

60
h-index

27257

107
g-index

173
all docs

173
docs citations

173
times ranked

19279
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional Characterization of Human Receptors for Short Chain Fatty Acids and Their Role in Polymorphonuclear Cell Activation. <i>Journal of Biological Chemistry</i> , 2003, 278, 25481-25489.	3.5	1,343
2	The CC chemokine CCL20 and its receptor CCR6. <i>Cytokine and Growth Factor Reviews</i> , 2003, 14, 409-426.	7.7	680
3	The role of CXC chemokines and their receptors in cancer. <i>Cancer Letters</i> , 2008, 267, 226-244.	7.3	573
4	Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4. <i>Journal of Experimental Medicine</i> , 1997, 186, 1383-1388.	8.8	564
5	Chemokine-Induced Macrophage Polarization in Inflammatory Conditions. <i>Frontiers in Immunology</i> , 2018, 9, 1930.	4.9	296
6	The unique structural and functional features of CXCL12. <i>Cellular and Molecular Immunology</i> , 2018, 15, 299-311.	9.9	256
7	CXCR3 ligands in disease and therapy. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 311-327.	7.7	251
8	Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. <i>European Journal of Immunology</i> , 2001, 31, 812-822.	3.3	250
9	Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV. <i>Journal of Biological Chemistry</i> , 1998, 273, 7222-7227.	3.5	238
10	Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands. <i>Frontiers in Immunology</i> , 2017, 8, 1970.	4.9	236
11	Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. <i>Blood</i> , 2001, 98, 3554-3561.	1.4	228
12	Identification of Biologically Active Chemokine Isoforms from Ascitic Fluid and Elevated Levels of CCL18/Pulmonary and Activation-regulated Chemokine in Ovarian Carcinoma. <i>Journal of Biological Chemistry</i> , 2002, 277, 24584-24593.	3.5	194
13	Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults. <i>Current Medicinal Chemistry</i> , 2016, 23, 1725-1755.	2.5	191
14	Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. <i>Journal of Experimental Medicine</i> , 2008, 205, 2085-2097.	8.8	161
15	Platelets Release CXCL4L1, a Nonallelic Variant of the Chemokine Platelet Factor-4/CXCL4 and Potent Inhibitor of Angiogenesis. <i>Circulation Research</i> , 2004, 95, 855-857.	10.7	153
16	Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78 ¹² into a most efficient monocyte attractant and CCR1 agonist. <i>Blood</i> , 2000, 96, 1674-1680.	1.4	151
17	Tumor angiogenesis revisited: Regulators and clinical implications. <i>Medicinal Research Reviews</i> , 2017, 37, 1231-1274.	11.6	145
18	Unique Regulation of CCL18 Production by Maturing Dendritic Cells. <i>Journal of Immunology</i> , 2003, 170, 3843-3849.	0.8	144

#	ARTICLE	IF	CITATIONS
19	Functional Comparison of Two Human Monocyte Chemotactic Protein-2 Isoforms, Role of the Amino-Terminal Pyroglutamic Acid and Processing by CD26/Dipeptidyl Peptidase IV. <i>Biochemistry</i> , 1998, 37, 12672-12680.	2.6	143
20	Truncation of Macrophage-derived Chemokine by CD26/ Dipeptidyl-Peptidase IV beyond Its Predicted Cleavage Site Affects Chemotactic Activity and CC Chemokine Receptor 4 Interaction. <i>Journal of Biological Chemistry</i> , 1999, 274, 3988-3993.	3.5	142
21	The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. <i>Cytokine and Growth Factor Reviews</i> , 2011, 22, 1-18.	7.7	141
22	Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. <i>European Journal of Immunology</i> , 1998, 28, 1262-1271.	3.3	130
23	Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. <i>Clinical Immunology</i> , 2011, 139, 177-184.	3.3	126
24	Pathological roles of the homeostatic chemokine CXCL12. <i>Cytokine and Growth Factor Reviews</i> , 2018, 44, 51-68.	7.7	123
25	Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. <i>Blood</i> , 2007, 110, 37-44.	1.4	117
26	The expression and role of CXC chemokines in colorectal cancer. <i>Cytokine and Growth Factor Reviews</i> , 2011, 22, 345-358.	7.7	115
27	Activity of Different Bicyclam Derivatives against Human Immunodeficiency Virus Depends on Their Interaction with the CXCR4 Chemokine Receptor. <i>Molecular Pharmacology</i> , 1999, 55, 67-73.	2.3	109
28	Synthesis and Structure-Activity Relationships of Phenylenebis(methylene)- Linked Bis-azamacrocycles That Inhibit HIV-1 and HIV-2 Replication by Antagonism of the Chemokine Receptor CXCR4. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 3971-3981.	6.6	108
29	Synergy between Coproduced CC and CXC Chemokines in Monocyte Chemotaxis through Receptor-Mediated Events. <i>Molecular Pharmacology</i> , 2008, 74, 485-495.	2.3	108
30	Synergy between proinflammatory ligands of G protein-coupled receptors in neutrophil activation and migration. <i>Journal of Leukocyte Biology</i> , 2004, 76, 185-194.	3.3	106
31	The cytokine-serum amyloid A-chemokine network. <i>Cytokine and Growth Factor Reviews</i> , 2016, 30, 55-69.	7.7	105
32	Regulation of the Immune Response by the Interaction of Chemokines and Proteases. <i>Advances in Immunology</i> , 2003, 81, 1-44.	7.9	103
33	Microbial Toll-like receptor ligands differentially regulate CXCL10/IP-10 expression in fibroblasts and mononuclear leukocytes in synergy with IFN- β and provide a mechanism for enhanced synovial chemokine levels in septic arthritis. <i>European Journal of Immunology</i> , 2003, 33, 3146-3153.	3.3	99
34	Granulocyte chemotactic protein-2 and related CXC chemokines: from gene regulation to receptor usage. <i>Journal of Leukocyte Biology</i> , 1997, 62, 563-569.	3.3	98
35	CXCR3 determines strain susceptibility to murine cerebral malaria by mediating β -lymphocyte migration toward IFN- β -induced chemokines. <i>European Journal of Immunology</i> , 2008, 38, 1082-1095.	3.3	98
36	Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. <i>Blood</i> , 2011, 117, 480-488.	1.4	97

#	ARTICLE	IF	CITATIONS
37	The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1825, 117-129.	7.6	96
38	TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis. <i>Laboratory Investigation</i> , 2006, 86, 902-916.	3.9	95
39	Diverging binding capacities of natural LD78 ² isoforms of macrophage inflammatory protein-1 [±] to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils. <i>European Journal of Immunology</i> , 2001, 31, 2170-2178.	3.3	93
40	The LD78 ² isoform of MIP-1 [±] is the most potent CCR5 agonist and HIV-1 [±] inhibiting chemokine. <i>Journal of Clinical Investigation</i> , 1999, 104, R1-R5.	8.2	93
41	Chemokines synergize in the recruitment of circulating neutrophils into inflamed tissue. <i>European Journal of Immunology</i> , 2005, 35, 1583-1591.	3.3	87
42	Citrullination of CXCL12 Differentially Reduces CXCR4 and CXCR7 Binding with Loss of Inflammatory and Anti-HIV-1 Activity via CXCR4. <i>Journal of Immunology</i> , 2009, 182, 666-674.	0.8	87
43	cis Requirements for the Efficient Production of Recombinant DNA Vectors Based on Autonomous Parvoviruses. <i>Human Gene Therapy</i> , 1999, 10, 1619-1632.	3.0	84
44	The CXC Chemokine GCP-2/CXCL6 Is Predominantly Induced in Mesenchymal Cells by Interleukin-1 ² and Is Down-Regulated by Interferon- ³ : Comparison with Interleukin-8/CXCL8. <i>Laboratory Investigation</i> , 2003, 83, 23-34.	3.9	84
45	Pathogenesis of malaria-associated acute respiratory distress syndrome. <i>Trends in Parasitology</i> , 2013, 29, 346-358.	3.3	84
46	Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon- ³ in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids. <i>Journal of Leukocyte Biology</i> , 2004, 75, 777-784.	3.3	82
47	Myofibroblasts in proliferative diabetic retinopathy can originate from infiltrating fibrocytes and through endothelial-to-mesenchymal transition (EndoMT). <i>Experimental Eye Research</i> , 2015, 132, 179-189.	2.7	80
48	Regulated Production and Molecular Diversity of Human Liver and Activation-Regulated Chemokine/Macrophage Inflammatory Protein-3 [±] from Normal and Transformed Cells. <i>Journal of Immunology</i> , 2000, 165, 4470-4477.	0.8	78
49	Studying Neutrophil Function in vitro: Cell Models and Environmental Factors. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 141-162.	3.5	78
50	CD26/dipeptidylpeptidase IV [±] chemokine interactions: double-edged regulation of inflammation and tumor biology. <i>Journal of Leukocyte Biology</i> , 2016, 99, 955-969.	3.3	77
51	CD26-processed RANTES(3 [±] 68), but not intact RANTES, has potent anti-HIV-1 activity. <i>Antiviral Research</i> , 1998, 39, 175-187.	4.2	75
52	Natural Substrates of Dipeptidyl Peptidase IV. <i>Advances in Experimental Medicine and Biology</i> , 2002, 477, 67-87.	0.0	73
53	PARC/CCL18 Is a Plasma CC Chemokine with Increased Levels in Childhood Acute Lymphoblastic Leukemia. <i>American Journal of Pathology</i> , 2003, 163, 2065-2075.	4.1	72
54	CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue. <i>European Journal of Immunology</i> , 2004, 34, 1992-2000.	3.3	68

#	ARTICLE	IF	CITATIONS
55	Chemokine isoforms and processing in inflammation and immunity. <i>Journal of Autoimmunity</i> , 2017, 85, 45-57.	6.7	68
56	Neutrophils: Underestimated Players in the Pathogenesis of Multiple Sclerosis (MS). <i>International Journal of Molecular Sciences</i> , 2020, 21, 4558.	4.2	67
57	Chemokine-protease interactions in cancer. <i>Seminars in Cancer Biology</i> , 2004, 14, 201-208.	9.8	65
58	Chemokines and other GPCR ligands synergize in receptor-mediated migration of monocyte-derived immature and mature dendritic cells. <i>Immunobiology</i> , 2014, 219, 218-229.	1.9	65
59	Differential induction of monocyte chemotactic protein-3 in mononuclear leukocytes and fibroblasts by interferon- γ and interferon- β reveals MCP-3 heterogeneity. <i>European Journal of Immunology</i> , 1999, 29, 678-685.	3.9	64
60	CXCR4 and CCR5 ligands cooperate in monocyte and lymphocyte migration and in inhibition of dual-tropic (R5/X4) HIV-1 infection. <i>European Journal of Immunology</i> , 2011, 41, 963-973.	3.3	64
61	Serum amyloid A chemoattracts immature dendritic cells and indirectly provokes monocyte chemotaxis by induction of cooperating CC and CXC chemokines. <i>European Journal of Immunology</i> , 2015, 45, 101-112.	3.3	61
62	Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies. <i>Arthritis Research and Therapy</i> , 2006, 8, R107.	3.6	59
63	Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects. <i>European Journal of Immunology</i> , 2009, 39, 843-857.	3.3	57
64	CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/CCL1 and vMIP-I. <i>European Journal of Immunology</i> , 2003, 33, 494-501.	3.3	56
65	The Proinflammatory and Proangiogenic Macrophage Migration Inhibitory Factor Is a Potential Regulator in Proliferative Diabetic Retinopathy. <i>Frontiers in Immunology</i> , 2019, 10, 2752.	4.9	55
66	CXCL6 antibody neutralization prevents lung inflammation and fibrosis in mice in the bleomycin model. <i>Journal of Leukocyte Biology</i> , 2013, 94, 1317-1323.	3.3	54
67	Selective induction of CCL18/PARC by staphylococcal enterotoxins in mononuclear cells and enhanced levels in septic and rheumatoid arthritis. <i>European Journal of Immunology</i> , 2001, 31, 3755-3762.	3.3	53
68	Possible mechanisms involved in chemokine synergy fine tuning the inflammatory response. <i>Immunology Letters</i> , 2012, 145, 10-14.	2.7	53
69	Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis. <i>Cancer Letters</i> , 2011, 302, 54-62.	7.3	52
70	The LD78 Isoform of MIP-1 β Is the Most Potent CC-Chemokine in Inhibiting CCR5-Dependent Human Immunodeficiency Virus Type 1 Replication in Human Macrophages. <i>Journal of Virology</i> , 2001, 75, 4402-4406.	3.5	50
71	Chemokines and gelatinases in the aqueous humor of patients with active uveitis. <i>American Journal of Ophthalmology</i> , 2004, 138, 401-411.	3.4	50
72	Recognition Versus Adaptive Up-regulation and Degradation of CC Chemokines by the Chemokine Decoy Receptor D6 Are Determined by Their N-terminal Sequence. <i>Journal of Biological Chemistry</i> , 2009, 284, 26207-26215.	3.5	49

#	ARTICLE	IF	CITATIONS
73	How post-translational modifications influence the biological activity of chemokines. <i>Cytokine</i> , 2018, 109, 29-51.	3.2	47
74	The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage. <i>Experimental Eye Research</i> , 2006, 83, 401-407.	2.7	46
75	CXC chemokine expression profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. <i>Immunobiology</i> , 2011, 216, 1004-1009.	1.9	46
76	Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2113-2123.	4.4	46
77	Interleukin-17 regulates chemokine and gelatinase B expression in fibroblasts to recruit both neutrophils and monocytes. <i>Immunobiology</i> , 2009, 214, 835-842.	1.9	44
78	MCP-3 (CCL7) delivered by parvovirus MVMP reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells. <i>International Journal of Cancer</i> , 2007, 120, 1364-1371.	5.4	43
79	Serum amyloid A1 \pm induces paracrine IL-8/CXCL8 via TLR2 and directly synergizes with this chemokine via CXCR2 and formyl peptide receptor 2 to recruit neutrophils. <i>Journal of Leukocyte Biology</i> , 2015, 98, 1049-1060.	3.3	43
80	The COOH-Terminal Peptide of Platelet Factor-4 Variant (CXCL4L1/PF-4var47-70) Strongly Inhibits Angiogenesis and Suppresses B16 Melanoma Growth <i>in vivo</i> . <i>Molecular Cancer Research</i> , 2010, 8, 322-334.	3.5	42
81	Truncation of CXCL12 by CD26 reduces its CXC chemokine receptor 4- and atypical chemokine receptor 3-dependent activity on endothelial cells and lymphocytes. <i>Biochemical Pharmacology</i> , 2017, 132, 92-101.	4.6	42
82	Identification of a blood-derived chemoattractant for neutrophils and lymphocytes as a novel CC chemokine, Regakine-1. <i>Blood</i> , 2001, 97, 2197-2204.	1.4	41
83	Protective role of IFN- γ in collagen-induced arthritis conferred by inhibition of mycobacteria-induced granulocyte chemotactic protein-2 production. <i>Journal of Leukocyte Biology</i> , 2007, 81, 1044-1053.	3.3	41
84	Differential CXC and CX3C Chemokine Expression Profiles in Aqueous Humor of Patients With Specific Endogenous Uveitic Entities. , 2018, 59, 2222.		41
85	CXCL4 and CXCL4L1 Differentially Affect Monocyte Survival and Dendritic Cell Differentiation and Phagocytosis. <i>PLoS ONE</i> , 2016, 11, e0166006.	2.5	41
86	Circulating bone marrow-derived endothelial precursor cells contribute to neovascularization in diabetic epiretinal membranes. <i>Acta Ophthalmologica</i> , 2011, 89, 222-228.	1.2	40
87	Diffusion Tensor Imaging Findings and Postconcussion Symptom Reporting Six Weeks Following Mild Traumatic Brain Injury. <i>Archives of Clinical Neuropsychology</i> , 2015, 30, 7-25.	0.5	39
88	Kinetics of peripheral blood neutrophils in severe coronavirus disease 2019. <i>Clinical and Translational Immunology</i> , 2021, 10, e1271.	3.9	39
89	Longitudinal changes in gingival crevicular fluid after placement of fixed orthodontic appliances. <i>American Journal of Orthodontics and Dentofacial Orthopedics</i> , 2011, 139, 735-744.	1.8	38
90	Neurotrophins and Neurotrophin Receptors in Proliferative Diabetic Retinopathy. <i>PLoS ONE</i> , 2013, 8, e65472.	2.5	38

#	ARTICLE	IF	CITATIONS
91	Serum Amyloid A1 (SAA1) Revisited: Restricted Leukocyte-Activating Properties of Homogeneous SAA1. <i>Frontiers in Immunology</i> , 2020, 11, 843.	4.9	37
92	The Cytokine Interleukin-6 and the Chemokines CCL20 and CXCL13 Are Novel Biomarkers of Specific Endogenous Uveitic Entities. , 2016, 57, 4606.		36
93	CXCL9-Derived Peptides Differentially Inhibit Neutrophil Migration In Vivo through Interference with Glycosaminoglycan Interactions. <i>Frontiers in Immunology</i> , 2017, 8, 530.	4.9	34
94	Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein-2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells. <i>Journal of Leukocyte Biology</i> , 2007, 82, 1519-1530.	3.3	33
95	Human DOCK2 Deficiency: Report of a Novel Mutation and Evidence for Neutrophil Dysfunction. <i>Journal of Clinical Immunology</i> , 2019, 39, 298-308.	3.8	33
96	Natural nitration of CXCL12 reduces its signaling capacity and chemotactic activity <i>in vitro</i> and abrogates intra-articular lymphocyte recruitment <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 62439-62459.	2.1	32
97	Structure/Function Relationships of CCR8 Agonists and Antagonists. <i>Journal of Biological Chemistry</i> , 2006, 281, 36652-36661.	3.5	31
98	Carcinoma cell-derived chemokines and their presence in oral fluid. <i>European Journal of Oral Sciences</i> , 2009, 117, 362-368.	1.6	31
99	Cytokine and CXC chemokine expression patterns in aqueous humor of patients with presumed tuberculous uveitis. <i>Cytokine</i> , 2012, 59, 377-381.	3.2	31
100	Osteoprotegerin Is a New Regulator of Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy. , 2017, 58, 3189.		31
101	Amine-reactive OVA multimers for auto-vaccination against cytokines and other mediators: perspectives illustrated for GCP-2 in <i>L. major</i> infection. <i>Journal of Leukocyte Biology</i> , 2011, 89, 1001-1007.	3.3	29
102	Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases. <i>Cellular and Molecular Immunology</i> , 2018, 15, 312-323.	9.9	29
103	Method Matters: Effect of Purification Technology on Neutrophil Phenotype and Function. <i>Frontiers in Immunology</i> , 2022, 13, 820058.	4.9	29
104	CXCL4 and CXCL4L1 in cancer. <i>Cytokine</i> , 2018, 109, 65-71.	3.2	26
105	The Unique Property of the CC Chemokine Regakine-1 to Synergize with Other Plasma-Derived Inflammatory Mediators in Neutrophil Chemotaxis Does Not Reside in Its NH2-Terminal Structure. <i>Molecular Pharmacology</i> , 2002, 62, 173-180.	2.3	25
106	Impact of National Institutes of Health Gastrointestinal PROMIS Measures in Clinical Practice: Results of a Multicenter Controlled Trial. <i>American Journal of Gastroenterology</i> , 2016, 111, 1546-1556.	0.4	25
107	The <i>CC</i> chemokines <i>CCL</i> 8, <i>CCL</i> 13 and <i>CCL</i> 20 are local inflammatory biomarkers of HLA-B*27-associated uveitis. <i>Acta Ophthalmologica</i> , 2019, 97, e122-e128.	1.2	25
108	Local Cytokine Expression Profiling in Patients with Specific Autoimmune Uveitic Entities. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 453-462.	1.9	25

#	ARTICLE	IF	CITATIONS
109	Evaluation of Proteoforms of the Transmembrane Chemokines CXCL16 and CX3CL1, Their Receptors, and Their Processing Metalloproteinases ADAM10 and ADAM17 in Proliferative Diabetic Retinopathy. <i>Frontiers in Immunology</i> , 2020, 11, 601639.	4.9	25
110	CXCL14 Preferentially Synergizes With Homeostatic Chemokine Receptor Systems. <i>Frontiers in Immunology</i> , 2020, 11, 561404.	4.9	24
111	Angiostatic, tumor inflammatory and anti-tumor effects of CXCL447-70 and CXCL4L147â€“70 in an EGF-dependent breast cancer model. <i>Oncotarget</i> , 2014, 5, 10916-10933.	2.1	24
112	Cytokines and serum amyloid A in the pathogenesis of hepatitis C virus infection. <i>Cytokine and Growth Factor Reviews</i> , 2019, 50, 29-42.	7.7	23
113	Efficacy of B Cell Depletion Therapy with Rituximab in Refractory Chronic Recurrent Uveitis Associated with Vogt-Koyanagi-Harada Disease. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 750-757.	1.9	23
114	Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer. <i>Human Pathology</i> , 2010, 41, 990-1001.	2.3	22
115	Citrullination as a novel posttranslational modification of matrix metalloproteinases. <i>Matrix Biology</i> , 2021, 95, 68-83.	3.7	22
116	Langerhans cell histiocytosis: a cytokine/chemokine-mediated disorder?. <i>European Cytokine Network</i> , 2011, 22, 148-153.	1.8	22
117	The T-lymphocyte chemoattractant Mig is highly expressed in vernal keratoconjunctivitis. <i>American Journal of Ophthalmology</i> , 2003, 136, 853-860.	3.4	21
118	CC chemokine ligand-2 synergizes with the nonchemokine G protein-coupled receptor ligand fMLP in monocyte chemotaxis, and it cooperates with the TLR ligand LPS via induction of CXCL8. <i>Journal of Leukocyte Biology</i> , 2009, 86, 671-680.	3.3	21
119	New Perspectives on the Immunopathogenesis and Treatment of Uveitis Associated With Vogt-Koyanagi-Harada Disease. <i>Frontiers in Medicine</i> , 2021, 8, 705796.	2.7	21
120	The turning away of serum amyloid A biological activities and receptor usage. <i>Immunology</i> , 2021, 163, 115-127.	4.4	20
121	PF-4var/CXCL4L1 Predicts Outcome in Stable Coronary Artery Disease Patients with Preserved Left Ventricular Function. <i>PLoS ONE</i> , 2012, 7, e31343.	2.5	20
122	CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase. <i>Angiogenesis</i> , 2014, 17, 631-640.	7.2	19
123	Expression of interleukin (<sc>IL</sc>)â€“10 family cytokines in aqueous humour of patients with specific endogenous uveitic entities: elevated levels of <sc>IL</sc>â€“19 in human leucocyte antigenâ€“B27â€“associated uveitis. <i>Acta Ophthalmologica</i> , 2019, 97, e780-e784.	1.2	16
124	The Chemokine-Based Peptide, CXCL9(74-103), Inhibits Angiogenesis by Blocking Heparan Sulfate Proteoglycan-Mediated Signaling of Multiple Endothelial Growth Factors. <i>Cancers</i> , 2021, 13, 5090.	3.8	16
125	Gene Cloning of a New Plasma CC Chemokine, Activating and Attracting Myeloid Cells in Synergy with Other Chemoattractantsâ€“,â€“. <i>Biochemistry</i> , 2001, 40, 11715-11722.	2.6	15
126	Contribution of intracellular Ca2+ stores to Ca2+ signaling during chemokinesis of human neutrophil granulocytes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2009, 1793, 1041-1049.	4.1	15

#	ARTICLE	IF	CITATIONS
127	Matrix Metalloproteinase-9-Generated COOH-, but Not NH ₂ -Terminal Fragments of Serum Amyloid A1 Retain Potentiating Activity in Neutrophil Migration to CXCL8, With Loss of Direct Chemotactic and Cytokine-Inducing Capacity. <i>Frontiers in Immunology</i> , 2018, 9, 1081.	4.9	15
128	Role of Chemokines in Vernal Keratoconjunctivitis. <i>International Ophthalmology Clinics</i> , 2003, 43, 33-39.	0.7	14
129	Identification and characterization of MIP-1 β /CCL3 isoform 2 from bovine serum as a potent monocyte/dendritic cell chemoattractant. <i>Biochemical Pharmacology</i> , 2013, 85, 789-797.	4.6	14
130	The Chemokine Platelet Factor-4 Variant (PF-4var)/CXCL4L1 Inhibits Diabetes-Induced Bloodâ€“Retinal Barrier Breakdown. , 2015, 56, 1956.		14
131	Role of Defensins in Tumor Biology. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5268.	4.2	14
132	Transforming Growth Factor Beta Switch in Aqueous Humor of Patients With Fuchs' Endothelial Corneal Dystrophy. , 2016, 57, 771.		13
133	The Role of Post-Translational Modifications of Chemokines by CD26 in Cancer. <i>Cancers</i> , 2021, 13, 4247.	3.8	13
134	Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis. <i>Virology</i> , 2013, 447, 221-232.	2.5	12
135	Neutrophils from Patients with Primary Ciliary Dyskinesia Display Reduced Chemotaxis to CXCR2 Ligands. <i>Frontiers in Immunology</i> , 2017, 8, 1126.	4.9	12
136	The ectoenzyme-side of matrix metalloproteinases (MMPs) makes inflammation by serum amyloid A (SAA) and chemokines go round. <i>Immunology Letters</i> , 2019, 205, 1-8.	2.7	11
137	Biochemical and Biological Characterization of Neutrophil Chemotactic Protein, a Novel Rabbit CXC Chemokine from Alveolar Macrophages. <i>Biochemistry</i> , 2000, 39, 14549-14557.	2.6	10
138	Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 589-603.	4.4	10
139	Anti-inflammatory effects of the GAG-binding CXCL9(74-103) peptide in dinitrofluorobenzene-induced contact hypersensitivity in mice. <i>Clinical and Experimental Allergy</i> , 2018, 48, 1333-1344.	2.8	10
140	Soluble cytokine receptor levels in aqueous humour of patients with specific autoimmune uveitic entities: sCD30 is a biomarker of granulomatous uveitis. <i>Eye</i> , 2020, 34, 1614-1623.	2.3	9
141	Tissue Inhibitor of Metalloproteinase-3 Ameliorates Diabetes-Induced Retinal Inflammation. <i>Frontiers in Physiology</i> , 2021, 12, 807747.	2.8	9
142	Recombinant Parvoviruses Armed to Deliver CXCL4L1 and CXCL10 Are Impaired in Their Antiangiogenic and Antitumoral Effects in a Kaposi Sarcoma Tumor Model Due To the Chemokines' Interference with the Virus Cycle. <i>Human Gene Therapy</i> , 2017, 28, 295-306.	3.0	8
143	Rapid and One-Step Transformation of LiAlH ₄ to Inorganic and Organic Anion Intercalated Li-Al Layered Double Hydroxides. <i>European Journal of Inorganic Chemistry</i> , 2019, 2019, 2412-2418.	2.2	8
144	From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8. <i>Frontiers in Immunology</i> , 2021, 12, 644725.	4.9	8

#	ARTICLE	IF	CITATIONS
145	The Antimicrobial Activity of Peripheral Blood Neutrophils Is Altered in Patients with Primary Ciliary Dyskinesia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6172.	4.2	8
146	Phenotypical and Functional Characterization of Neutrophils in Two Pyrin-Associated Auto-inflammatory Diseases. <i>Journal of Clinical Immunology</i> , 2021, 41, 1072-1084.	3.8	7
147	Affinity and Specificity for Binding to Glycosaminoglycans Can Be Tuned by Adapting Peptide Length and Sequence. <i>International Journal of Molecular Sciences</i> , 2022, 23, 447.	4.2	7
148	Molecular cloning and characterization of pig, cow and sheep MAdCAM-1 cDNA and the demonstration of cross-reactive epitopes amongst mammalian homologues+. <i>Tissue Antigens</i> , 2006, 67, 419-426.	0.8	6
149	Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6. <i>Biochemical Pharmacology</i> , 2004, 68, 1947-1955.	4.6	5
150	The role of chemokines and their receptors in uveitis. <i>International Ophthalmology</i> , 2007, 27, 321-327.	1.5	5
151	Peroxynitrite Exposure of CXCL12 Impairs Monocyte, Lymphocyte and Endothelial Cell Chemotaxis, Lymphocyte Extravasation in vivo and Anti-HIV-1 Activity. <i>Frontiers in Immunology</i> , 2018, 9, 1933.	4.9	5
152	Induction of Chemokines by Hepatitis C Virus Proteins: Synergy of the Core Protein with Interleukin-1 β and Interferon- γ in Liver Bystander Cells. <i>Journal of Interferon and Cytokine Research</i> , 2020, 40, 195-206.	1.3	5
153	CD40 Ligand-CD40 Interaction Is an Intermediary between Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 15582.	4.2	5
154	Relative distribution and biological characterization of CXCL4L1 isoforms in platelets from healthy donors. <i>Biochemical Pharmacology</i> , 2017, 145, 123-131.	4.6	4
155	Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78 into a most efficient monocyte attractant and CCR1 agonist. <i>Blood</i> , 2000, 96, 1674-1680.	1.4	4
156	Isolation of human monocyte chemotactic proteins and study of their producer and responder cells by immunotests and bioassays. <i>Methods in Enzymology</i> , 1997, 287, 109-127.	1.7	3
157	Biological Characterization of Commercial Recombinantly Expressed Immunomodulating Proteins Contaminated with Bacterial Products in the Year 2020: The SAA3 Case. <i>Mediators of Inflammation</i> , 2020, 2020, 1-17.	3.1	3
158	Macrophage-Myofibroblast Transition Contributes to Myofibroblast Formation in Proliferative Vitreoretinal Disorders. <i>International Journal of Molecular Sciences</i> , 2023, 24, 13510.	4.2	3
159	Inhibition of renal fibrosis with a human CXCL9-derived glycosaminoglycan-binding peptide. <i>Clinical and Translational Immunology</i> , 2022, 11, e1370.	3.9	2
160	Absence of CCR2 Promotes Proliferation of Alveolar Macrophages That Control Lung Inflammation in Acute Respiratory Distress Syndrome in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12920.	4.2	2
161	Data management and visualization of wearable medical devices assisted by artificial intelligence. <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2021, 10, 1.	2.3	1
162	Selective induction of CCL18/PARC by staphylococcal enterotoxins in mononuclear cells and enhanced levels in septic and rheumatoid arthritis. <i>European Journal of Immunology</i> , 2001, 31, 3755.	3.3	1

#	ARTICLE	IF	CITATIONS
163	Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. <i>Journal of Cell Biology</i> , 2008, 182, i9-i9.	5.2	0
164	Effect on neutrophil migration and antimicrobial functions by the Bruton's tyrosine kinase inhibitors tolebrutinib, evobrutinib and fenebrutinib. <i>Journal of Leukocyte Biology</i> , 0, , .	3.3	0